339 related articles for article (PubMed ID: 32502201)
1. Targeting miR-27a/VE-cadherin interactions rescues cerebral cavernous malformations in mice.
Li J; Zhao Y; Choi J; Ting KK; Coleman P; Chen J; Cogger VC; Wan L; Shi Z; Moller T; Zheng X; Vadas MA; Gamble JR
PLoS Biol; 2020 Jun; 18(6):e3000734. PubMed ID: 32502201
[TBL] [Abstract][Full Text] [Related]
2. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations.
Cuttano R; Rudini N; Bravi L; Corada M; Giampietro C; Papa E; Morini MF; Maddaluno L; Baeyens N; Adams RH; Jain MK; Owens GK; Schwartz M; Lampugnani MG; Dejana E
EMBO Mol Med; 2016 Jan; 8(1):6-24. PubMed ID: 26612856
[TBL] [Abstract][Full Text] [Related]
3. Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations.
Zhu Y; Wu Q; Xu JF; Miller D; Sandalcioglu IE; Zhang JM; Sure U
Neurosurg Focus; 2010 Sep; 29(3):E1. PubMed ID: 20809750
[TBL] [Abstract][Full Text] [Related]
4. Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27.
Young JA; Ting KK; Li J; Moller T; Dunn L; Lu Y; Moses J; Prado-Lourenço L; Khachigian LM; Ng M; Gregory PA; Goodall GJ; Tsykin A; Lichtenstein I; Hahn CN; Tran N; Shackel N; Kench JG; McCaughan G; Vadas MA; Gamble JR
Blood; 2013 Oct; 122(16):2911-9. PubMed ID: 24009229
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.
Ting KK; Zhao Y; Shen W; Coleman P; Yam M; Chan-Ling T; Li J; Moller T; Gillies M; Vadas MA; Gamble JR
Diabetologia; 2019 Feb; 62(2):322-334. PubMed ID: 30443753
[TBL] [Abstract][Full Text] [Related]
6. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.
McDonald DA; Shenkar R; Shi C; Stockton RA; Akers AL; Kucherlapati MH; Kucherlapati R; Brainer J; Ginsberg MH; Awad IA; Marchuk DA
Hum Mol Genet; 2011 Jan; 20(2):211-22. PubMed ID: 20940147
[TBL] [Abstract][Full Text] [Related]
7. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
Stockton RA; Shenkar R; Awad IA; Ginsberg MH
J Exp Med; 2010 Apr; 207(4):881-96. PubMed ID: 20308363
[TBL] [Abstract][Full Text] [Related]
8. Low fluid shear stress conditions contribute to activation of cerebral cavernous malformation signalling pathways.
Li J; Zhao Y; Coleman P; Chen J; Ting KK; Choi JP; Zheng X; Vadas MA; Gamble JR
Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165519. PubMed ID: 31369819
[TBL] [Abstract][Full Text] [Related]
9. The CCM1-CCM2 complex controls complementary functions of ROCK1 and ROCK2 that are required for endothelial integrity.
Lisowska J; Rödel CJ; Manet S; Miroshnikova YA; Boyault C; Planus E; De Mets R; Lee HH; Destaing O; Mertani H; Boulday G; Tournier-Lasserve E; Balland M; Abdelilah-Seyfried S; Albiges-Rizo C; Faurobert E
J Cell Sci; 2018 Aug; 131(15):. PubMed ID: 30030370
[TBL] [Abstract][Full Text] [Related]
10. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.
Zhou Z; Tang AT; Wong WY; Bamezai S; Goddard LM; Shenkar R; Zhou S; Yang J; Wright AC; Foley M; Arthur JS; Whitehead KJ; Awad IA; Li DY; Zheng X; Kahn ML
Nature; 2016 Apr; 532(7597):122-6. PubMed ID: 27027284
[TBL] [Abstract][Full Text] [Related]
11. Caveolae-mediated Tie2 signaling contributes to CCM pathogenesis in a brain endothelial cell-specific Pdcd10-deficient mouse model.
Zhou HJ; Qin L; Jiang Q; Murray KN; Zhang H; Li B; Lin Q; Graham M; Liu X; Grutzendler J; Min W
Nat Commun; 2021 Jan; 12(1):504. PubMed ID: 33495460
[TBL] [Abstract][Full Text] [Related]
12. Neuroinflammation Plays a Critical Role in Cerebral Cavernous Malformation Disease.
Lai CC; Nelsen B; Frias-Anaya E; Gallego-Gutierrez H; Orecchioni M; Herrera V; Ortiz E; Sun H; Mesarwi OA; Ley K; Gongol B; Lopez-Ramirez MA
Circ Res; 2022 Nov; 131(11):909-925. PubMed ID: 36285625
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.
Kar S; Bali KK; Baisantry A; Geffers R; Samii A; Bertalanffy H
J Mol Neurosci; 2017 Feb; 61(2):178-188. PubMed ID: 28181149
[TBL] [Abstract][Full Text] [Related]
14. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.
Lopez-Ramirez MA; Lai CC; Soliman SI; Hale P; Pham A; Estrada EJ; McCurdy S; Girard R; Verma R; Moore T; Lightle R; Hobson N; Shenkar R; Poulsen O; Haddad GG; Daneman R; Gongol B; Sun H; Lagarrigue F; Awad IA; Ginsberg MH
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34043589
[TBL] [Abstract][Full Text] [Related]
15. microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin.
Muramatsu F; Kidoya H; Naito H; Sakimoto S; Takakura N
Oncogene; 2013 Jan; 32(4):414-21. PubMed ID: 22391569
[TBL] [Abstract][Full Text] [Related]
16. Impaired retinoic acid signaling in cerebral cavernous malformations.
Grdseloff N; Boulday G; Rödel CJ; Otten C; Vannier DR; Cardoso C; Faurobert E; Dogra D; Tournier-Lasserve E; Abdelilah-Seyfried S
Sci Rep; 2023 Apr; 13(1):5572. PubMed ID: 37019926
[TBL] [Abstract][Full Text] [Related]
17. High-throughput sequencing of the entire genomic regions of CCM1/KRIT1, CCM2 and CCM3/PDCD10 to search for pathogenic deep-intronic splice mutations in cerebral cavernous malformations.
Rath M; Jenssen SE; Schwefel K; Spiegler S; Kleimeier D; Sperling C; Kaderali L; Felbor U
Eur J Med Genet; 2017 Sep; 60(9):479-484. PubMed ID: 28645800
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of the angiogenic phenotype and genotype of the endothelia derived from sporadic cerebral cavernous malformations.
Zhu Y; Wu Q; Fass M; Xu JF; You C; Müller O; Sandalcioglu IE; Zhang JM; Sure U
Neurosurgery; 2011 Sep; 69(3):722-31; discussion 731-2. PubMed ID: 21471841
[TBL] [Abstract][Full Text] [Related]
19. EndMT contributes to the onset and progression of cerebral cavernous malformations.
Maddaluno L; Rudini N; Cuttano R; Bravi L; Giampietro C; Corada M; Ferrarini L; Orsenigo F; Papa E; Boulday G; Tournier-Lasserve E; Chapon F; Richichi C; Retta SF; Lampugnani MG; Dejana E
Nature; 2013 Jun; 498(7455):492-6. PubMed ID: 23748444
[TBL] [Abstract][Full Text] [Related]
20. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex.
Stahl S; Gaetzner S; Voss K; Brackertz B; Schleider E; Sürücü O; Kunze E; Netzer C; Korenke C; Finckh U; Habek M; Poljakovic Z; Elbracht M; Rudnik-Schöneborn S; Bertalanffy H; Sure U; Felbor U
Hum Mutat; 2008 May; 29(5):709-17. PubMed ID: 18300272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
